Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Vaccine, Vaccine, Vaccine, Vaccine, Vaccine · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Group 1 | EXPERIMENTAL | rLP2086 vaccine at visits 1, 2 and 5, saline at visit 3 |
| Group 2 | EXPERIMENTAL | rLP2086 vaccine at visits 1, 3, and 5, saline at visit 2 |
| Group 3 | EXPERIMENTAL | rLP2086 vaccine at visits 1, and 5, saline at visits 2 and 3 |
| Group 4 | EXPERIMENTAL | rLP2086 at visits 1 and 3, saline at visits 2 and 5 |
| Group 5 | EXPERIMENTAL | rLP2086 at visits 3 and 5, saline at visits 1 and 2 |
| Name | Type | Description |
|---|---|---|
| Vaccine | BIOLOGICAL | rLP2086 vaccine at visits 1, 2 and 5, saline at visit 3 |
Inclusion Criteria: * Evidence of a personally signed and dated informed consent document indicating that the parent/legally acceptable representative and/or subject has been informed of all pertinent aspects of the study. * Parent/legally acceptable representative and/or subjects who are willing a...
1 mg, 5 mg, 10 mg is an investigational drug being developed by Pfizer, Inc. (PFE). It is being studied for use in neoplasms, non-Hodgkin lymphoma, meningococcal vaccine, growth disorder, hypercholesterolemia, and non-squamous lung cancer. The drug is currently in Phase 1 clinical development.
1 mg, 5 mg, 10 mg is being developed by Pfizer, Inc., a biopharmaceutical company traded on the New York Stock Exchange under the ticker symbol PFE. The drug is currently in Phase 1 clinical development for multiple indications including neoplasms and growth disorder.
1 mg, 5 mg, 10 mg is currently in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities. The drug is being studied for conditions such as neoplasms, non-Hodgkin lymphoma, and growth disorder.
1 mg, 5 mg, 10 mg has been studied in clinical trials including NCT00037791 and NCT00039910, which evaluated its safety and efficacy in preventing thrombocytopenia in patients with neoplasms and lymphoma. These trials were Phase 3 and have been completed.
1 mg, 5 mg, 10 mg is associated with the investigational drug PN-152,243, also referred to as PN-196,444. Clinical trials such as NCT00037791 and NCT00039910 studied the safety and efficacy of PN-152,243/PN-196,444 in preventing thrombocytopenia.